Clinical trials: Primary Brain Tumour
Cancer, Brain Tumors
[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
Despite significant advances in the understanding of brain tumor biology and genetics as well as improvements in surgical techniques, radiotherapy administration, and chemotherapy methods, many primary brain tumors remain…
- Trial name
- NCT00707343
- Testing
- FLT-PET Imaging
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Utah
Cancer
Advanced MRI Sequences for Radiation Therapy Treatment Planning
The purpose of this study is to determine if it would be helpful to use advanced MRI imaging techniques to take additional views of the tumor target for radiation treatment planning or treatment follow-up MRI.
- Trial name
- NCT02340715
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Medical College of Wisconsin
Brain Tumors, Osteoporosis
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.
- Conditions
- Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
- Trial name
- NCT00301873
- Testing
- IV Zometa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Malignant Brain Tumors
(68^Ga)-GaPSMA-11 PET/MR-imaging of Malignant Intra-axial Brain Tumors
PSMA is a transmembrane protein specifically expressed in the vascular endothelium of malignant brain tumors, most notably glioblastoma and not in healthy brain parenchyma.
- Trial name
- NCT05798273
- Testing
- intra-arterial injection, synchronous PET/MRI scan, Radiopharmacon Contrast agent
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Erasmus Medical Center
Primary Central Nervous System Neoplasms
Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- SIOP-LGG-2004 (NCT00276640)
- Testing
- vincristine, carboplatin, vincristine, carboplatin, etoposide, radiation therapy
- Where
- 13 sites in Austria, Belgium and 10 more
- Volunteers
- 3,417 people
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
Mood, Cancer Brain
Managing Cancer and Living Meaningfully
The purpose of this study is to pilot test an empirically supported psychotherapeutic intervention, Managing Cancer and Living Meaningfully (CALM).
- Trial name
- CALM (NCT04646213)
- Testing
- Managing Cancer and Living Meaningfully (CALM) Therapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Virginia Commonwealth University
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Depression
Managing Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed With a Primary Brain Tumor
Background: Psychological distress affects many people diagnosed with a primary central nervous system tumor (CNST). Distress can include negative feelings such as anger, fear, or sadness.
- Trial name
- NCT04852302
- Testing
- Cancer and Living Meaningfully (CALM) Therapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Primary, Cognitive Impairment
Cognitive Rehabilitation in Brain Tumor Patients After Neurosurgery
Many patients with primary brain tumors experience cognitive deficits and cognitive rehabilitation programs aim to alleviate these deficits.The cognitive rehabilitation program developed by the investigators proved effective in a…
- Trial name
- NCT03373487
- Testing
- The cognitive rehabilitation program ReMind
- Where
- 3 sites in Netherlands
- Volunteers
- 115 people
- Sponsor
- Elisabeth-TweeSteden Ziekenhuis
Brain Metastases, Generalized Malignancy, Primary
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
The main purpose of this study is to see whether addition of TPI 287 to FSRT is safe and tolerable. Researchers also want to find out if adding TPI 287 to FSRT can help with better controlling the growth of brain lesions in…
- Conditions
- Brain Metastases, Generalized Malignancy, Primary, Brain Lesions
- Trial name
- NCT02187822
- Testing
- TPI 287, Fractionated Stereotactic Radiotherapy (FSRT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lennox Gastaut Syndrome, Dravet Syndrome
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
- Conditions
- Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
- Trial name
- NCT05044819
- Testing
- Cannabidiol
- Where
- 26 sites in United States
- Volunteers
- 154 people
- Sponsor
- Jazz Pharmaceuticals
Solid Tumors, Metastatic Cancer to Liver
Organ-Specific Differences in Immunotherapy Response Among Metastatic Cancer Patients
This study examines how tumors in different metastatic organs respond to immune checkpoint inhibitor (ICB) therapy in real-world clinical practice.
- Conditions
- Solid Tumors, Metastatic Cancer to Liver, Metastatic Cancer to the Bone, Metastatic Cancer to the Lung
- Trial name
- NCT07631611
- Where
- China
- Volunteers
- 938 people
- Sponsor
- Wenlong Zhong, MD
Advanced Solid Tumor, RAS Mutation
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients…
- Conditions
- Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
- Trial name
- NCT05831995
- Testing
- ABM-168
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- ABM Therapeutics Corporation
Prostatic Neoplasms, Esophageal Neoplasms
Tumor Hypoxia With HX4 PET in Several Diseases
Regulation of tissue oxygen homeostasis is critical for cell function, proliferation and survival. Evidence for this continues to accumulate along with our understanding of the complex oxygen-sensing pathways present within…
- Conditions
- Prostatic Neoplasms, Esophageal Neoplasms, Neoplasm Metastases, Brain, Rectal Neoplasms
- Trial name
- HX4 SD (NCT02584400)
- Testing
- Injection with the hypoxia tracer [18F]HX4,
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- Maastricht Radiation Oncology
Ataxia Telangiectasia
Whole Body MRI for Cancer Surveillance in A-T
Ataxia Telangiectasia (A-T) is an inherited disorder characterised by cerebellar neurodegeneration, immunodeficiency and respiratory disease.
- Trial name
- NCT05252819
- Testing
- Magnetic Resonance Imaging and an optional blood test
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- University of Nottingham
Glioma, Glioneuronal Tumor
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on…
- Conditions
- Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors
- Trial name
- NCT05259605
- Testing
- Observational
- Where
- 42 sites in Austria, Belgium and 10 more
- Volunteers
- 1,650 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Primary Brain Neoplasm
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
This trial studies how an imaging agent, hyperpolarized carbon C 13 pyruvate, works in diagnosing glioma in patients with brain tumors.
- Trial name
- NCT03830151
- Testing
- Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Spectroscopic Imaging
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
CNS Lymphoma, CNS Brain Cancer
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma
The purpose of this study is to determine the safety of this new treatment offered in this study. PCNSL can be cured in less than half of patients with standard treatment, a combination of chemotherapy and brain radiation.
- Conditions
- CNS Lymphoma, CNS Brain Cancer, Non-Hodgkin's Lymphoma
- Trial name
- PCNSL (NCT00596154)
- Testing
- Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Central Nervous System Neoplasms, Primary Brain Neoplasms
Biomarker Analysis of Central Nervous System Tumors
Background: The number of people who get tumors of the brain or central nervous system (CNS) is lower than other cancers. But these tumors cause a higher rate of serious effects and even death.
- Conditions
- Central Nervous System Neoplasms, Primary Brain Neoplasms, Neoplasms, Brain, Cancer of the Brain
- Trial name
- NCT02692898
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)